Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Volume is sooooo low, that the Wall Street Bets-like crowd doesn’t want to jump in. Or so they say on StockTwits
Yup! 4 years for me. Painful how low this thing is right now.
In 3 years I’ve learned .... it can always go lower.
I wonder how much the crooks at GALT paid for that pump piece, and why there's no disclaimer on the "CNA Finance" site?
They haven't updated their disclosures since 2019 (which of course is illegal), but I think we all know GALT paid them for the steaming pile of garbage masquerading as a news item:
https://cnafinance.com/relationship-disclosures/
* * $GALT Video Chart 04-14-2021 * *
Link to Video - click here to watch the technical chart video
I was waaaay off : 20 Mill per hour ???
$GALT is screaming for the top, squeezing the shorts, after a peer reviewed data publication suggests it's sitting on a goldmine. https://cnafinance.com/galectin-therapeutics-galt-stock-climbs-on-data-publication/
After the Cancer publication, will the volume tomorrow be 500,000 shares or 15 Mill ?
* * $GALT Video Chart 04-06-2021 * *
Link to Video - click here to watch the technical chart video
Is any audio available from that presentation yesterday ?
It was a scam promoted by undisclosed stock promoters then, and it doesn’t look like much has changed since then.
Adam Feuerstein had their number years ago: https://www.thestreet.com/investing/stocks/biotech-stock-mailbag-aspenbio-10741455
I've been in this dog since it was Pro-Pharma. Lost tons. Any good reason to stay??? Anyone???
December presentation
https://investor.galectintherapeutics.com/static-files/e02430e7-e6f8-4b46-b174-461df8d85a84
Last 10-Q
https://www.sec.gov/ix?doc=/Archives/edgar/data/1133416/000119312520288500/d204131d10q.htm
They could be close to partnership. More data soon as well imo.
Started accumulating.
I saw on Stock Twits a link to an article that referenced that GALT’s Belapectin *IS* being studied in an animal pre-clinical trial.
HNY BooDog and glty
Took a starter 2.25. Happy new year!!
They seem to be averse to giving shareholders anything to hope for in the next 12 months. Everything is downplayed; almost got the impression that NASH-RX was being done as a lark. Of course I knew that wasn’t true, but after that CC many months ago ... well, it was depressing. That ceo is gone.
I seriously don’t think they are pursuing Covid at all.
Yep, such is life in bio plays unfortunately
That was a missed opportunity and very disappointing. I thought this new guy was going to be more cognizant of PR and shareholder communications.
Buckysherm said,
They talked about Covid affecting the NASH trial, but nothing about research for GRMD02 treating Covid.
I was wrong. The entire call was NASH-Rx and restating company history.
Well someone's sure been dumping this into the close. We'll see what the CEO has to say in about 2 minutes lol.
Todays premarket action was clearly a strong indication that GALT's new CEO has some real & relevant material progress to announce soon right bucky, imho anyways tick tick tick tick tick...
I inserted a goofy face to indicate that I was just kidding on the last sentence, but it came out as question marks.
I am expecting almost all of the call to be on the NASH 2b/3 trial. I had hoped for some Covid news some time ago, but have given up on that. Covid would have taken away from Shlevin’s golf game, but now that he’s not CEO, that might be a possibility. ??
Agreed buddy! Stars certainly appear to be aligning, and it's a great time for the new CEO to be brought in here!
If they dont talk about COVID we need to all complain. I think they will though. The argument is laid out so well.
Agreed Chess Master! I'm definitely looking forward to tuning into the Conference Call at 4pm market close woot-woot!
Did you read this article? This makes an amazing case for use as a COVID-19 treatment.
Here's the information on todays market close Conference Call folks>>>
Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020
September 22 2020 - 08:04AM
GlobeNewswire Inc.
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will host an investor conference call and webinar to discuss the Company’s NASH-RX clinical trial and to introduce its new CEO, Joel Lewis. The Investor Call is scheduled for Tuesday, September 29, 2020, at 4:00 p.m. EDT.
The presentation can be accessed by dialing (844) 899-6544 and entering the conference ID: 3695038 or at the following webcast link: https://edge.media-server.com/mmc/p/hmudntyg. A copy of the presentation to be used for the call can be found on the Company’s website at https://investor.galectintherapeutics.com/investor-relations.
The call is expected to last one hour, including a Q&A session that will follow the formal remarks. The Company encourages the investment community to submit their questions in advance to: info@galectintherapeutics.com and no later than Friday, September 25th at 4 PM EDT.
Let's see what the new CEO has to say as they definitely appear to have secured the necessary/required funding to conduct real deal trials now right bucky!
So todays 4pm market close GALT CC should be very revealing imho glty!
Galectin Therapeutics (GALT) is Due for a COVID-19 Makeover
GALT up 36% on COVID-19 speculation
https://emerginggrowth.com/galectin-therapeutics-galt-is-due-for-a-covid-19-makeover/
The former CEO Shlevin announced the 2b/3 trial months ago, and I got the impression that it was done as a lark and the company didn’t expect the trial to do well. Of course I knew that ain’t true, but that’s the tenor / timbre (?) he conveyed at the time.
Wakey wakey eggs & bakey;)
Looking forward to the CC at market close today and hearing what the new CEO has to say about the pending clinical trials glty
After about 3 years of “gloom, despair and agony on me” an up day like this is a delight.
You have to subscribe to see the article. I thought that after a few weeks such articles could be viewed by everyone. What’s the deal?
Copied from another board :
“Furthermore, we detected about ~3.4x upregulation of LGALS3BP, which is known to induce the expression of IL-6 by stromal cells in Galectin-3-dependent manner (Silverman et al., 2012). Of note, Galectin-3 has long been considered an attractive drug target in combating various forms of TGF-ß-mediated fibrosis and pathological inflammatory conditions (Brinchmann et al., 2018; Mackinnon et al., 2012; Shen et al.,2018; Yu Lili et al., 2013). Inhibition of Galectin-3-mediated signalling pathways hence represents another potential therapeutic target against COVID-19.”
https://www.medrxiv.org/content/10.1101/2020.04.27.20081810v1
Did you post the correct link? If you did, at what point in the video is Galactin discussed?
Great video about Galectins and the role in COVID-19
About time for another GALT chart, right Clay ?
The company doesn’t talk because there has been NOTHING to talk about for 2 years ! Other than the rights offering and a couple of patents.
GALT has initiated the adaptive Ph2b/Ph3 with a very favorable primary end point (progression to Varices)-it is now posted on the FDA Clinical Trials site:
https://clinicaltrials.gov/ct2/show/NCT04365868
This end point is a duplicate of the positive results in the original Ph2 CX trial and points to a strong likelihood of a success in the Ph3
I'm surprised that GALT hasn't done a Press Release yet about this but it's possible there is additional news that will be included with this.
Stock is up 13% today and this is the likely reason for that increase.
Followers
|
79
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3840
|
Created
|
03/21/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |